Integrated behavioral intervention to improve HIV/AIDS treatment adherence and reduce HIV transmission

American Journal of Public Health

Volumn 101, Issue 3, 2011, Pages 531-538

  Kalichman, Seth C ^a   Cherry, Chauncey ^a   Kalichman, Moira O ^a   Amaral, Christina M ^a   White, Denise ^a   Pope, Howard ^a   Swetzes, Connie ^a   Eaton, Lisa ^a   Macy, Rene ^a   Cain, Demetria ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; BEHAVIOR THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE TRANSMISSION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVENTION STUDY; MALE; METHODOLOGY; PATIENT COMPLIANCE; POISSON DISTRIBUTION; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SEXUALLY TRANSMITTED DISEASE; TREATMENT OUTCOME; UNITED STATES; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; BEHAVIOR THERAPY; FEMALE; GEORGIA; HIV INFECTIONS; HUMANS; INTERVENTION STUDIES; MALE; PATIENT COMPLIANCE; POISSON DISTRIBUTION; RISK REDUCTION BEHAVIOR; SEXUALLY TRANSMITTED DISEASES, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 79951623405     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2010.197608     Document Type: Article

References (44)

1. Lima VD, Harrigan R, Bangsberg DR, et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr. 2009;50(5):529-536.
2. Dieffenbach CW, Fauci AS. Universal voluntary testing and treatment for prevention of HIV transmission. JAMA. 2009;301(22):2380-2382.
3. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375 (9731):2092-2098.
4. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009; 373(9657):48-57.
5. Blower SM, Gershengorn HB, Grant RM. A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science. 2000;287(5453):650-654. (Pubitemid 30070912)
6. Wilson DP, Law MG, Grulich AE. Relation between HIV viral load and infectiousness: a model-based analysis. Lancet. 2008;372(9635):314-320. (Pubitemid 352020440)
7. Vernazza P, Hirschel B, Bernasconi E, Flepp M. HIV transmission under highly active antiretroviral therapy. Lancet. 2008;372(9652):1806-1807; author reply 1807.
8. Vernazza PL, Troiani L, Flepp MJ, et al. Potent antiretroviral treatment of HIV infection results in suppression of the seminal shedding of HIV. AIDS. 2000; 14(2):117-121. (Pubitemid 30116436)
9. Vernazza P, Hirschel B, Bernasconi E, Flepp M. HIVpositive individuals without additional sexually transmitted diseases (STD) and on effective anti-retroviral therapy are sexually non-infectious. Schweiz Arzteztg. 2008;89(5):165-169.
10. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342(13):921-929. (Pubitemid 30177052)
11. Wawer MJ, Gray RH, Sewankarnbo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis. 2005;191(9): 1403-1409. (Pubitemid 40563350)
12. Kashuba AD, Dyer JR, Kramer LM, Raasch RH, Eron JJ, Cohen MS. Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1999;43(8):1817-1826. (Pubitemid 29395171)
13. Vernazza PL, Gilliam BL, Dyer J, Fiscus SA, Eron JJ, Cohen F. Quantification of HIV in semen: correlation with antiviral treatment and immune status. AIDS. 1997;11(8):987-993. (Pubitemid 27259520)
14. Parienti JJ, Das-Douglas M, Massari V, et al. Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS ONE. 2008;3(7):e2783.
15. Bangsberg DR, Kroetz DL, Deeks SG. Adherenceresistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep. 2007;4(2):65-72. (Pubitemid 46806622)
16. Parienti JJ, Ragland K, Lucht F, et al. Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication. Clin Infect Dis. 2010;50(8):1192-1197.
17. Diamond C, Richardson JL, Milan J, et al. Use of and adherence to antiretroviral therapy is associated with decreased sexual risk behavior in HIV clinic patients. J Acquir Immune Defic Syndr. 2005;39(2):211-218. (Pubitemid 40741121)
18. Ping LH, Cohen MS, Hoffman I, et al. Effects of genital tract inflammation on human immunodeficiency virus type 1 V3 populations in blood and semen. J Virol. 2000;74(19):8946-8952.
19. Brewer TH, Metsch LR, Zenilman JM. Use of a public sexually transmitted disease clinic by known HIV-positive adults: decreased self-reported risk behavior and increased disease incidence. J Acquir Immune Defic Syndr. 2002;29(3):289-294. (Pubitemid 34208538)
20. Kalichman SC, Rompa D, Cage M. Sexually transmitted infections among HIV seropositive men and women. Sex Transm Infect. 2000;76(5):350-354.
21. Pilcher CD, Chuan Tien H, Eron JJ, et al. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis. 2004;189(10):1785- 1792. (Pubitemid 38657214)
22. Kalichman SC, DiBerto G, Eaton L. Human immunodeficiency virus viral load in blood plasma and semen: review and implications of empirical findings. Sex Transm Dis. 2008;35(1):55-60. (Pubitemid 351619353)
23. Crepaz N, Hart TA, Marks G. Highly active antiretroviral therapy and sexual behavior: a meta-analytic review. JAMA. 2004;292(2):224-236. (Pubitemid 38918000)
24. Kalichman SC, Rompa D. HIV treatment adherence and unprotected sex practices in people receiving antiretroviral therapy. Sex Transm Infect. 2003;79(1):59-61. (Pubitemid 36237829)
25. Kalichman SC, Rompa D, Austin J, LukeW, DiFonzo K. Viral load, perceived infectivity, and unprotected intercourse. J Acquir Immune Defic Syndr. 2001;28(3): 303-305. (Pubitemid 33055459)
26. Eaton LA, Kalichman S. Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies. Curr HIV/AIDS Rep. 2007;4(4):165-172.
27. Kalichman SC. Co-occurrence of treatment nonadherence and continued HIV transmission risk behaviors: implications for positive prevention interventions. Psychosom Med. 2008;70(5):593-597.
28. Crepaz N, Lyles CM, Wolitski RJ, et al. Do prevention interventions reduce HIV risk behaviours among people living with HIV? A meta-analytic review of controlled trials. AIDS. 2006;20(2):143-157.
29. Johnson MO, Charlebois E, Morin SF, Remien RH, Chesney MA. Effects of a behavioral intervention on antiretroviral medication adherence among people living with HIV: the Healthy Living Project Randomized Controlled Study. J Acquir Immune Defic Syndr. 2007;46(5): 574-580. (Pubitemid 350191050)
30. Healthy Living Project Team. Effects of a behavioral intervention to reduce risk of transmission among people living with HIV/AIDS: the Healthy Living Project Randomized Controlled Study. J Acquir Immune Defic Syndr. 2007;44(2):213-221.
31. El-Sadr WM, Mayer KH, Hodder SL. AIDS in America-forgotten but not gone. N Engl J Med. 2010; 362(11):967-970.
32. Janis IL, Mann L. Decision-Making: A Psychological Analysis of Conflict, Choice, and Commitment. New York: Free Press; 1977.
33. Gribble JN, Miller HG, Cooley PC, Catania JA, Pollack L, Turner CF. The impact of T-ACASI interviewing on reported drug use among men who have sex with men. Subst Use Misuse. 2000;35(6-8):869-890.
34. Bangsberg DR, Hecht FM, Charlebois ED, Chesney M, Moss A. Comparing objective measures of adherence to HIV antiretroviral therapy: electronic medication monitors and unannounced pill counts. AIDS Behav. 2001;5(3):275-281. (Pubitemid 35364540)
35. Kalichman SC, Amaral CM, Cherry C, et al. Monitoring antiretroviral adherence by unannounced pill counts conducted by telephone: reliability and criterionrelated validity. HIV Clin Trials. 2008;9(5):298-308.
36. Napper L, Fisher DG, Reynolds GL, Johnson ME. HIV risk behavior self-report reliability at different recall periods. AIDS Behav. 2010;35(4):350-354.
37. Schroder KE, Carey MP, Vanable P. Methodological challenges in research on sexual risk behavior: I. Item content, scaling, and data analytic options. Ann Behav Med. 2003;26(2):76-103. (Pubitemid 37271596)
38. Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAuliffe TL. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol. 2000;19(2):124-133.
39. Kalichman SC, Cain D, Cherry C, Kalichman M, Pope H. Pillboxes and antiretroviral adherence: prevalence of use, perceived benefits, and implications for electronic medication monitoring devices. AIDS Patient Care STDS. 2005;19(12):833-839. (Pubitemid 43100338)
40. Kalichman SC, Cain D, Weinhardt L, et al. Experimental components analysis of brief theory-based HIVAIDS risk reduction counseling for sexually transmitted infection patients. Health Psychol. 2005;24(2):198-208. (Pubitemid 40365682)
41. Kalichman SC, Eaton L, Cain D, et al. Changes in HIV treatment beliefs and sexual risk behaviors among gay and bisexual men, 1997-2002. Health Psychol. 2007;26(5):650-656. (Pubitemid 47488602)
42. Amico KR, Harman JJ, Johnson BT. Efficacy of antiretroviral therapy adherence interventions: a research synthesis of trials, 1996 to 2004. J Acquir Immune Defic Syndr. 2006;41(3):285-297.
43. Jurs SG, Glass GV. The effect of experimental mortality on the internal and external validity of the randomized comparative experiment. J Exp Educ. 1971; 40(1):62-66.
44. Mills EJ, Cooper C. Simple, effective interventions are key to improving adherence in marginalized populations. Clin Infect Dis. 2007;45(7):916-917. (Pubitemid 47580388)